vimarsana.com
Home
Live Updates
Transposon Announces Interim Results from a Phase 2 Study of
Transposon Announces Interim Results from a Phase 2 Study of
Transposon Announces Interim Results from a Phase 2 Study of TPN-101 for the Treatment of Progressive Supranuclear Palsy to be Presented at the AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases
24-Week data show TPN-101 is the first treatment for PSP to reduce NfL levels, a key biomarker of neurodegeneration in tauopathies such as PSP and Alzheimer's disease
Related Keywords
Lisbon ,
Lisboa ,
Portugal ,
Andrew Satlin ,
Rick Orr ,
Dennis Podlesak ,
International Conference On Alzheimer ,
Transposon Therapeutics Inc ,
International Conference ,
Chief Medical Officer ,
Chief Executive Officer ,
Nucleoside Reverse Transcriptase Inhibitor ,
Progressive Supranuclear Palsy ,
Region ,